n-vinyl-2-pyrrolidinone has been researched along with Pulmonary Disease, Chronic Obstructive in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albuquerque, FC; Barnwell, SL; Deshmukh, VR; Fiorella, D; Heck, DV; Hu, YC; McDougall, CG; Nixon, RR | 1 |
| Aoki, Y; Kawabata, Y; Kojo, Y; Mizumoto, T; Ogawa, K; Onoue, S; Sato, H; Wada, K; Yamada, S | 1 |
2 other study(ies) available for n-vinyl-2-pyrrolidinone and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Histopathological assessment of fatal ipsilateral intraparenchymal hemorrhages after the treatment of supraclinoid aneurysms with the Pipeline Embolization Device.
Topics: Aged; Anticoagulants; Autopsy; Biocompatible Materials; Carotid Artery, Internal; Cerebral Angiography; Embolization, Therapeutic; Fatal Outcome; Female; Humans; Intracranial Aneurysm; Intracranial Hemorrhages; Male; Middle Aged; Nervous System Diseases; Neurosurgical Procedures; Postoperative Complications; Povidone; Pulmonary Disease, Chronic Obstructive; Spectroscopy, Fourier Transform Infrared | 2014 |
Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats.
Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents; Asthma; Chemistry, Pharmaceutical; Cyclosporine; Drug Carriers; Emulsifying Agents; Emulsions; Glycerides; Lactose; Male; Particle Size; Povidone; Powders; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Sprague-Dawley; Solubility | 2012 |